Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2018

Open Access 01-12-2018 | Research article

Urinary angiostatin, CXCL4 and VCAM-1 as biomarkers of lupus nephritis

Authors: Chi Chiu Mok, Samar Soliman, Ling Yin Ho, Fatma A. Mohamed, Faten Ismail Mohamed, Chandra Mohan

Published in: Arthritis Research & Therapy | Issue 1/2018

Login to get access

Abstract

Background

The aim was to study urinary angiostatin, CXC chemokine ligand 4 (CXCL4) and vascular cell adhesion molecule-1 (VCAM-1) as biomarkers of renal disease in systemic lupus erythematosus (SLE).

Method

Patients who fulfilled ≥ 4 American College of Rheumatology (ACR) criteria for SLE with active renal, active non-renal or inactive disease, and a group of healthy controls were studied. Urine samples were assayed for angiostatin, CXCL4 and VCAM-1 by ELISA, and normalized by creatinine. Receiver operating characteristic analysis was performed to obtain the best cutoff values to calculate the performance of these markers in differentiating the different groups of patients as compared to anti-double-stranded DNA (anti-dsDNA) and complement C3. Correlation between these urinary biomarkers and various renal parameters was also tested.

Results

Patients with SLE (n = 227; 80 with inactive SLE, 67 with active non-renal disease and 80 with active renal disease; 94% women; age 39.2 ± 13.8 years) and 53 controls (96% women) were studied. All were ethnic Chinese. Urinary angiostatin, CXCL4 and VCAM-1 (normalized for creatinine) were significantly higher in patients with active renal disease than in patients with active non-renal disease, patients with inactive SLE and controls. These markers correlated significantly with total SLE disease activity index (SLEDAI) and renal SLEDAI scores, and with the urinary protein-to-creatinine ratio. Urine angiostatin exhibited higher specificity and sensitivity in differentiating active renal from active non-renal SLE (area under the curve (AUC) 0.87) than serum anti-dsDNA/C3. Urine CXCL4 (AUC 0.64) and VCAM-1 (AUC 0.73), on the other hand, performed similarly to anti-dsDNA/C3. All three markers performed comparably to anti-dsDNA/C3 in distinguishing active from inactive SLE. In a subgroup of 68 patients with paired renal biopsy, the urinary levels of these proteins did not differ significantly between the proliferative and non-proliferative types of lupus nephritis. Urinary CXCL4 and VCAM-1 correlated significantly with the histologic activity score, and urinary angiostatin correlated significantly with proteinuria in this subgroup.

Conclusions

Urinary angiostatin, CXCL4 and VCAM-1 are potential biomarkers for SLE, in particular lupus nephritis. Further longitudinal studies are necessary to delineate the performance of these markers in predicting renal flares and prognosis in SLE patients.
Literature
2.
go back to reference Mok CC. Towards new avenues in the management of lupus glomerulonephritis. Nat Rev Rheumatol. 2016;12:221–34.CrossRefPubMed Mok CC. Towards new avenues in the management of lupus glomerulonephritis. Nat Rev Rheumatol. 2016;12:221–34.CrossRefPubMed
3.
go back to reference Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65:2154–60.CrossRefPubMed Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65:2154–60.CrossRefPubMed
4.
go back to reference Donadio Jr JV, Hart GM, Bergstralh EJ, Holley KE. Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus. 1995;4:109–15.CrossRefPubMed Donadio Jr JV, Hart GM, Bergstralh EJ, Holley KE. Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus. 1995;4:109–15.CrossRefPubMed
5.
go back to reference Mok CC, Wong RW, Lau CS. Lupus nephritis in Southern Chinese patients: clinicopathologic findings and long-term outcome. Am J Kidney Dis. 1999;34:315–23.CrossRefPubMed Mok CC, Wong RW, Lau CS. Lupus nephritis in Southern Chinese patients: clinicopathologic findings and long-term outcome. Am J Kidney Dis. 1999;34:315–23.CrossRefPubMed
6.
go back to reference Jolly M, Toloza S, Goker B, Rourre-Tessier G, Clark A, Navarra S, et al. Disease specific quality of life in patients with lupus nephritis. Lupus. 2018;27:257–64.CrossRefPubMed Jolly M, Toloza S, Goker B, Rourre-Tessier G, Clark A, Navarra S, et al. Disease specific quality of life in patients with lupus nephritis. Lupus. 2018;27:257–64.CrossRefPubMed
7.
go back to reference Mok CC, Cheung MY, Ho LY, Yu KL, To CH. Risk and predictors of work disability in Chinese patients with systemic lupus erythematosus. Lupus. 2008;17:1103–7.CrossRefPubMed Mok CC, Cheung MY, Ho LY, Yu KL, To CH. Risk and predictors of work disability in Chinese patients with systemic lupus erythematosus. Lupus. 2008;17:1103–7.CrossRefPubMed
11.
go back to reference Wu T, Du Y, Han J, Singh S, Xie C, Guo Y, et al. Urinary angiostatin–a novel putative marker of renal pathology chronicity in lupus nephritis. Mol Cell Proteomics. 2013;12:1170–9.CrossRefPubMedPubMedCentral Wu T, Du Y, Han J, Singh S, Xie C, Guo Y, et al. Urinary angiostatin–a novel putative marker of renal pathology chronicity in lupus nephritis. Mol Cell Proteomics. 2013;12:1170–9.CrossRefPubMedPubMedCentral
13.
go back to reference Landolt-Marticorena C, Prokopec SD, Morrison S, Noamani B, Bonilla D, Reich H, et al. A discrete cluster of urinary biomarkers discriminates between active systemic lupus erythematosus patients with and without glomerulonephritis. Arthritis Res Ther. 2016;18:218.CrossRefPubMedPubMedCentral Landolt-Marticorena C, Prokopec SD, Morrison S, Noamani B, Bonilla D, Reich H, et al. A discrete cluster of urinary biomarkers discriminates between active systemic lupus erythematosus patients with and without glomerulonephritis. Arthritis Res Ther. 2016;18:218.CrossRefPubMedPubMedCentral
14.
15.
go back to reference Ikeda Y, Fujimoto T, Ameno M, Shiiki H, Dohi K. Relationship between lupus nephritis activity and the serum level of soluble VCAM-1. Lupus. 1998;7:347–54.CrossRefPubMed Ikeda Y, Fujimoto T, Ameno M, Shiiki H, Dohi K. Relationship between lupus nephritis activity and the serum level of soluble VCAM-1. Lupus. 1998;7:347–54.CrossRefPubMed
16.
go back to reference Spronk PE, Bootsma H, Huitema MG, Limburg PC, Kallenberg CG. Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clin Exp Immunol. 1994;97:439–44.CrossRefPubMedPubMedCentral Spronk PE, Bootsma H, Huitema MG, Limburg PC, Kallenberg CG. Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clin Exp Immunol. 1994;97:439–44.CrossRefPubMedPubMedCentral
17.
go back to reference Lewis MJ, Vyse S, Shields AM, Zou L, Khamashta M, Gordon PA, et al. Improved monitoring of clinical response in systemic lupus erythematosus by longitudinal trend in soluble vascular cell adhesion molecule-1. Arthritis Res Ther. 2016;18:5. https://doi.org 10.1186/s13075-015-0896-7.CrossRefPubMedPubMedCentral Lewis MJ, Vyse S, Shields AM, Zou L, Khamashta M, Gordon PA, et al. Improved monitoring of clinical response in systemic lupus erythematosus by longitudinal trend in soluble vascular cell adhesion molecule-1. Arthritis Res Ther. 2016;18:5. https://​doi.​org 10.1186/s13075-015-0896-7.CrossRefPubMedPubMedCentral
18.
go back to reference Molad Y, Miroshnik E, Sulkes J, Pitlik S, Weinberger A, Monselise Y. Urinary soluble VCAM-1 in systemic lupus erythematosus: a clinical marker for monitoring disease activity and damage. Clin Exp Rheumatol. 2002;20:403–6.PubMed Molad Y, Miroshnik E, Sulkes J, Pitlik S, Weinberger A, Monselise Y. Urinary soluble VCAM-1 in systemic lupus erythematosus: a clinical marker for monitoring disease activity and damage. Clin Exp Rheumatol. 2002;20:403–6.PubMed
19.
go back to reference Kiani AN, Wu T, Fang H, Zhou XJ, Ahn CW, Magder LS, et al. Urinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritis. J Rheumatol. 2012;39:1231–7.CrossRefPubMedPubMedCentral Kiani AN, Wu T, Fang H, Zhou XJ, Ahn CW, Magder LS, et al. Urinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritis. J Rheumatol. 2012;39:1231–7.CrossRefPubMedPubMedCentral
20.
go back to reference Singh S, Wu T, Xie C, Vanarsa K, Han J, Mahajan T, et al. Urine VCAM-1 as a marker of renal pathology activity index in lupus nephritis. Arthritis Res Ther. 2012;14:R164.CrossRefPubMedPubMedCentral Singh S, Wu T, Xie C, Vanarsa K, Han J, Mahajan T, et al. Urine VCAM-1 as a marker of renal pathology activity index in lupus nephritis. Arthritis Res Ther. 2012;14:R164.CrossRefPubMedPubMedCentral
21.
22.
go back to reference van Bon L, Affandi AJ, Broen J, Christmann RB, Marijnissen RJ, Stawski L, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med. 2014;370:433–43.CrossRefPubMed van Bon L, Affandi AJ, Broen J, Christmann RB, Marijnissen RJ, Stawski L, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med. 2014;370:433–43.CrossRefPubMed
23.
go back to reference Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.CrossRefPubMed Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.CrossRefPubMed
24.
go back to reference Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353:2550–8.CrossRefPubMed Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353:2550–8.CrossRefPubMed
25.
go back to reference Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005;142:953–62.CrossRefPubMed Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005;142:953–62.CrossRefPubMed
26.
go back to reference Petri M, Hellmann D, Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol. 1992;19:53–9.PubMed Petri M, Hellmann D, Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol. 1992;19:53–9.PubMed
27.
go back to reference O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994;79:315–28.CrossRefPubMed O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994;79:315–28.CrossRefPubMed
28.
go back to reference Sharma MR, Tuszynski GP, Sharma MC. Angiostatin-induced inhibition of endothelial cell proliferation/apoptosis is associated with the down-regulation of cell cycle regulatory protein cdk5. J Cell Biochem. 2004;91:398–409.CrossRefPubMed Sharma MR, Tuszynski GP, Sharma MC. Angiostatin-induced inhibition of endothelial cell proliferation/apoptosis is associated with the down-regulation of cell cycle regulatory protein cdk5. J Cell Biochem. 2004;91:398–409.CrossRefPubMed
29.
go back to reference Aulakh GK, Balachandran Y, Liu L, Singh B. Angiostatin inhibits activation and migration of neutrophils. Cell Tissue Res. 2014;355:375–96.CrossRefPubMed Aulakh GK, Balachandran Y, Liu L, Singh B. Angiostatin inhibits activation and migration of neutrophils. Cell Tissue Res. 2014;355:375–96.CrossRefPubMed
30.
go back to reference Mu W, Long DA, Ouyang X, Agarwal A, Cruz PE, Roncal CA, et al. Angiostatin overexpression is associated with an improvement in chronic kidney injury by an anti-inflammatory mechanism. Am J Physiol Renal Physiol. 2009;296:F145–52.CrossRefPubMed Mu W, Long DA, Ouyang X, Agarwal A, Cruz PE, Roncal CA, et al. Angiostatin overexpression is associated with an improvement in chronic kidney injury by an anti-inflammatory mechanism. Am J Physiol Renal Physiol. 2009;296:F145–52.CrossRefPubMed
31.
go back to reference Pigott R, Dillon LP, Hemingway IH, Gearing AJ. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun. 1992;187:584–9.CrossRefPubMed Pigott R, Dillon LP, Hemingway IH, Gearing AJ. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun. 1992;187:584–9.CrossRefPubMed
32.
go back to reference Klimiuk PA, Fiedorczyk M, Sierakowski S, Chwiecko J. Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis. Scand J Rheumatol. 2007;36:345–50.CrossRefPubMed Klimiuk PA, Fiedorczyk M, Sierakowski S, Chwiecko J. Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis. Scand J Rheumatol. 2007;36:345–50.CrossRefPubMed
33.
go back to reference Romagnani P, Maggi L, Mazzinghi B, Cosmi L, Lasagni L, Liotta F, et al. CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production. J Allergy Clin Immunol. 2005;116:1372–9.CrossRefPubMed Romagnani P, Maggi L, Mazzinghi B, Cosmi L, Lasagni L, Liotta F, et al. CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production. J Allergy Clin Immunol. 2005;116:1372–9.CrossRefPubMed
34.
go back to reference Liu CY, Battaglia M, Lee SH, Sun QH, Aster RH, Visentin GP. Platelet factor 4 differentially modulates CD4 + CD25+ (regulatory) versus CD4 + CD25- (nonregulatory) T cells. J Immunol. 2005;174:2680–6.CrossRefPubMed Liu CY, Battaglia M, Lee SH, Sun QH, Aster RH, Visentin GP. Platelet factor 4 differentially modulates CD4 + CD25+ (regulatory) versus CD4 + CD25- (nonregulatory) T cells. J Immunol. 2005;174:2680–6.CrossRefPubMed
35.
go back to reference Aidoudi S, Bikfalvi A. Interaction of PF4 (CXCL4) with the vasculature: a role in atherosclerosis and angiogenesis. Thromb Haemost. 2010;104:941–8.CrossRefPubMed Aidoudi S, Bikfalvi A. Interaction of PF4 (CXCL4) with the vasculature: a role in atherosclerosis and angiogenesis. Thromb Haemost. 2010;104:941–8.CrossRefPubMed
36.
go back to reference Pitsilos S, Hunt J, Mohler ER, Prabhakar AM, Poncz M, Dawicki J, et al. Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters. Thromb Haemost. 2003;90:1112–20.PubMed Pitsilos S, Hunt J, Mohler ER, Prabhakar AM, Poncz M, Dawicki J, et al. Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters. Thromb Haemost. 2003;90:1112–20.PubMed
37.
go back to reference Schaub S, Nickerson P, Rush D, Mayr M, Hess C, Golian M, et al. Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am J Transplant. 2009;9:1347–53.CrossRefPubMed Schaub S, Nickerson P, Rush D, Mayr M, Hess C, Golian M, et al. Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am J Transplant. 2009;9:1347–53.CrossRefPubMed
38.
go back to reference Wu T, Xie C, Wang HW, Zhou XJ, Schwartz N, Calixto S, et al. Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol. 2007;179:7166–75.CrossRefPubMed Wu T, Xie C, Wang HW, Zhou XJ, Schwartz N, Calixto S, et al. Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol. 2007;179:7166–75.CrossRefPubMed
Metadata
Title
Urinary angiostatin, CXCL4 and VCAM-1 as biomarkers of lupus nephritis
Authors
Chi Chiu Mok
Samar Soliman
Ling Yin Ho
Fatma A. Mohamed
Faten Ismail Mohamed
Chandra Mohan
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2018
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-017-1498-3

Other articles of this Issue 1/2018

Arthritis Research & Therapy 1/2018 Go to the issue